Where can I buy fotantinib/fotantinib in the country?

Fostamatinib is an oral spleen tyrosine kinase inhibitor (SYK inhibitor) developed by Rigel Pharmaceuticals in the United States. It is mainly used to treat chronic immune thrombocytopenia (ITP) and other diseases. The drug was approved by the US FDA for marketing in 2018 under the trade name Tavalisse. At present, this drug has not yet been officially launched in mainland China and belongs to the category of innovative prescription drugs that have not yet been introduced. Therefore, if patients want to obtain the drug, they must purchase it through regular overseas channels or licensed imports.

At present, there are no official pharmacies or hospitals in China that can directly purchase the original version of fostatinib. Patients can learn about drug purchasing methods through cross-border medical or third-party pharmaceutical service platforms registered with the National Medical Products Administration. Some qualified cross-border drug service platforms can assist patients to legally order original drugs from pharmacies in countries such as the United States, Germany or Japan. Due to different drug transportation and tariff policies, prices will fluctuate to a certain extent. According to public information from overseas markets, fostatinib is available in two packages: 100 mg × 60 tablets and 150 mg × 60 tablets. The price is equivalent to RMB 20,000 to RMB 40,000, making it a relatively high-priced targeted drug.

If patients consider purchasing drugs overseas when they are not yet available in the country, they should give priority to channels with legal filings to avoid purchasing unregulated drugs. At the same time, you need to follow your doctor's instructions for medication management, because this drug is a prescription drug and it is not appropriate to adjust the dosage or use it instead. In the future, as more drugs for the treatment of immune platelet diseases are registered in China, fostatinib is expected to be approved for marketing in China, and the price and medical insurance policies will become clearer by then. At present, domestic clinical experts generally believe that the launch of fostatinib will provide a new treatment direction for ITP patients who have poor response to traditional treatments.

Reference materials:https://go.drugbank.com/drugs/DB12010